NAFLD/NASH-related liver fibrosis: from mechanisms to prevention

While the successful treatment of hepatitis B and C reduced the burden of liver disease related to viral hepatitis, NAFLD) or NASH) are nowadays the leading causes of hepatic fibrosis worldwide. In this review, F. Tacke et al. (Charité University Medicine, Berlin, Germany) discuss recent advances in antifibrotic prevention and therapy...
PUBLISHED IN: Ann Transl Med 2021

Commentary

While the successful treatment of hepatitis B and C reduced the burden of liver disease related to viral hepatitis, NAFLD) or NASH) are nowadays the leading causes of hepatic fibrosis worldwide. In this review, F. Tacke et al. (Charité University Medicine, Berlin, Germany) discuss recent advances in antifibrotic prevention and therapy.

For the authors, “tackling NAFLD-associated fibrosis from different directions by combinatorial drug treatment and effective lifestyle changes hold the greatest prospects.”

Share the article
Dr. G. Bozet, MD

Dr. G. Bozet, MD

Articles: 174

Leave a Reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES